A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
Vassilios I. Avramis(Children’s Minnesota - St. Paul Hospital), John S. Holcenberg(Children's of Alabama), Susan Sencer(University of Minnesota Children's Hospital), Michael N. Needle(Children’s Minnesota - St. Paul Hospital), Gregory H. Reaman(National Cancer Institute), Antonia Periclou(Children’s Minnesota - St. Paul Hospital), Lawrence J. Ettinger(Saint Peter's University Hospital), Paul S. Gaynon(University of Southern California), Alice G. Ettinger(Children’s Minnesota - St. Paul Hospital), Pracad Mathew(Children’s Minnesota - St. Paul Hospital), Janet Franklin(Children's Hospital of Los Angeles), Joseph P. Neglia(University of Minnesota), Fataneh Majlessipour(Cedars-Sinai Medical Center), Joanne M. Hilden(Children's Hospital Colorado), Harland N. Sather(Children's Oncology Group), Beverly J. Lange(Philadelphia University), Lewis Cohen(Children’s Minnesota - St. Paul Hospital), Bruce Bostrom(Minnesota West Community & Technical College)
Cited by 496
Related Papers
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
|New England Journal of Medicine|1999|1.2k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920